Utilization jumped and March revenue rose 28%, yet gross margin collapsed to 12% because they're buying volume with price cuts.
Thesis: This is a profitless recovery. The volume bottom is likely in (March +28% MoM is a hard signal), but the unit economics are broken. They are filling the fab by conceding on price ('retaining flexibility'), resulting in a 12.4% gross margin. Without high-end AI exposure or CoWoS capacity, they are a leverage-free play on the legacy semi cycle. You don't own the recovery until they prove they can raise prices.
Verdict: HOLD — Conviction: MEDIUM
Catalyst: Q2 gross margin report. If utilization climbs but margins stagnate below 15%, the 'commoditized capacity' thesis is confirmed.
Key Risk: Memory recovery (36% of rev) lags further. Management expects Q3, but IDMs are cutting production aggressively. If Q3 recovery slips to Q4, the thesis breaks.
The Tell: When asked about price pressure, the Chairman admitted to 'retaining some flexibility in the OEM price' for low-end testers to improve utilization. You don't cut prices if you have a real bottleneck.
Friction Level: MODERATE_FRICTION — Bulls see the 28% March revenue spike as the cycle turn. Bears see the 210bps margin collapse and admitted 'price flexibility' as proof of structural commoditization.
Report not found
The report data is no longer available. Please return to the archive.